Biotechnology Case Study

Cogentum has built substantial know how and understanding of the biotechnology industry. Our work in this area is producing significant results for our clients.

Acrux

While many Biotech's claim their technology will entitle them to a share of the market, listed Australian Biotech Acrux (ACR) went one step further. In order to test the hypothesis that their new solution for Low Testosterone would be accepted, adopted and prescribed by Amecian Physicians  - PCP's, Urologists and Endocrinologists, Acrux undertook a value assessment study.

The project discovered some powerful insights about the Physician experience with low testosterone therapy and how they interact with patients, regulators and Pharma during diagnosis and treatment. The research produced a clear measure of the likely adoption of the Acrux solution and potential switching rates from all the major competitive treatments.

By working closely with the Acrux management team and leveraging our significant American resources we were able to rigorously test Acrux's hypothesis and provide tangible, objective evidence to support Acrux's licensing strategy.

"The results have elevated our negotiating position exponentially." _{Dr Richard Treagus, CEO Acrux}

Click here to view the press release

To talk through your challenges and discuss how Cogentum could add value, please contact us by clicking here